Printer Friendly

Researchers develop breathalyser test for lung cancer detection.

M2 PHARMA-June 20, 2014-Researchers develop breathalyser test for lung cancer detection


20 June 2014 - Israeli, US and UK researchers have developed a breathalyser test that is able to accurately diagnose lung cancer and identify its stage of progression.

The test, integrating a NaNose nanotech chip, detects the unique signature of volatile organic compounds (VOCs) in exhaled breath. VOCs are chemicals produced by lung cancer tumours.

Findings from a study, involving 358 patients who were either diagnosed with or at risk for lung cancer, showed that the test accurately distinguished healthy people from patients with early-stage lung cancer in 85% of the time, as well as healthy individuals from those with advanced lung cancer in 82% of the cases. Furthermore, the device accurately differentiated early from advanced lung cancer in 79% of the time.

US firm Alpha Szenszor has licensed the technology and intends to commercially launch it over the next few years.

A new, smaller version of the test, able to be plugged into a computer's USB port, has also been developed.

((Comments on this story may be sent to

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jun 20, 2014
Previous Article:Augurex, NRC join forces to develop novel rheumatoid arthritis therapies.
Next Article:uniQure signs contract with Medison Pharma.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters